Moomoo AI 已提取核心訊息
TransCode Therapeutics, Inc., a biopharmaceutical company, was the subject of a recent Schedule 13G/A filing with the Securities and Exchange Commission (SEC), dated December 31, 2023. The amendment was filed by Tang Capital Partners, LP, Tang Capital Management, LLC, and Kevin Tang, the manager of Tang Capital Management. The filing indicates that these entities and individual collectively own 0 shares of TransCode Therapeutics' common stock and consequently represent 0.0% of the class. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is typically used by persons who have acquired beneficial ownership of more than 5% of a class of equity securities. The filing also includes a certification by Kevin Tang, stating that the shares were not acquired for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect. The principal business office address for the reporting persons is listed as 4747 Executive Drive, Suite 210, San Diego, CA 92121.
TransCode Therapeutics, Inc., a biopharmaceutical company, was the subject of a recent Schedule 13G/A filing with the Securities and Exchange Commission (SEC), dated December 31, 2023. The amendment was filed by Tang Capital Partners, LP, Tang Capital Management, LLC, and Kevin Tang, the manager of Tang Capital Management. The filing indicates that these entities and individual collectively own 0 shares of TransCode Therapeutics' common stock and consequently represent 0.0% of the class. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is typically used by persons who have acquired beneficial ownership of more than 5% of a class of equity securities. The filing also includes a certification by Kevin Tang, stating that the shares were not acquired for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect. The principal business office address for the reporting persons is listed as 4747 Executive Drive, Suite 210, San Diego, CA 92121.
生物製藥公司TransCode Therapeutics, Inc. 是最近於2023年12月31日向美國證券交易委員會（SEC）提交的附表13G/A文件的主題。該修正案由唐資本合夥人有限責任公司、唐資本管理有限責任公司和唐資本管理公司經理唐凱文提交。文件顯示，這些實體和個人共擁有TransCode Therapeutics普通股的0股，因此佔該類別的0.0％。該申請是根據1934年《證券交易法》第13d-1（c）條提交的，該法通常由獲得某類股票證券5％以上的受益所有權的人使用。該文件還包括唐凱文的證明，表明收購這些股票不是爲了改變或影響發行人的控制權，也不是與任何具有此類目的或效果的交易有關。申報人的主要辦公地址列爲行政大道4747號，210套房，加利福尼亞州聖地亞哥92121。
生物製藥公司TransCode Therapeutics, Inc. 是最近於2023年12月31日向美國證券交易委員會（SEC）提交的附表13G/A文件的主題。該修正案由唐資本合夥人有限責任公司、唐資本管理有限責任公司和唐資本管理公司經理唐凱文提交。文件顯示，這些實體和個人共擁有TransCode Therapeutics普通股的0股，因此佔該類別的0.0％。該申請是根據1934年《證券交易法》第13d-1（c）條提交的，該法通常由獲得某類股票證券5％以上的受益所有權的人使用。該文件還包括唐凱文的證明，表明收購這些股票不是爲了改變或影響發行人的控制權，也不是與任何具有此類目的或效果的交易有關。申報人的主要辦公地址列爲行政大道4747號，210套房，加利福尼亞州聖地亞哥92121。
有用
沒用